Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
ADXN 
Addex Therapeutics Ltd (ADXN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/26/2025: ADXN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $30
1 Year Target Price $30
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.5% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.84M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 1 | Beta 2.1 | 52 Weeks Range 6.51 - 12.05 | Updated Date 12/27/2025 |
52 Weeks Range 6.51 - 12.05 | Updated Date 12/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-12-04 | When - | Estimate - | Actual -2.0989 |
Profitability
Profit Margin - | Operating Margin (TTM) -1403.58% |
Management Effectiveness
Return on Assets (TTM) -15.9% | Return on Equity (TTM) -72.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7735107 | Price to Sales(TTM) 62.09 |
Enterprise Value 7735107 | Price to Sales(TTM) 62.09 | ||
Enterprise Value to Revenue 195.05 | Enterprise Value to EBITDA -0.76 | Shares Outstanding 1231998 | Shares Floating 93856293 |
Shares Outstanding 1231998 | Shares Floating 93856293 | ||
Percent Insiders - | Percent Institutions 0.02 |
Upturn AI SWOT
Addex Therapeutics Ltd
Company Overview
History and Background
Addex Therapeutics Ltd was founded in 2002 as Addex Pharmaceuticals, a spin-off from the Swiss Federal Institute of Technology Lausanne (EPFL). The company focused on developing orally available small molecule allosteric modulators. Key milestones include its listing on the SIX Swiss Exchange in 2007 and the NASDAQ in 2008. In 2011, it rebranded to Addex Therapeutics. The company has undergone several strategic shifts, including a focus on neurological and psychiatric disorders.
Core Business Areas
- Neurological and Psychiatric Disorders: Addex Therapeutics focuses on developing novel therapeutics for neurological and psychiatric disorders by modulating G protein-coupled receptors (GPCRs) using its allosteric modulator technology. Their lead programs target conditions such as Parkinson's disease, major depressive disorder, and post-traumatic stress disorder.
- Rare Diseases: The company is also exploring opportunities in rare diseases where there is a significant unmet medical need and where their allosteric modulation approach could offer therapeutic benefits.
Leadership and Structure
Addex Therapeutics is led by a management team with expertise in drug development, neuroscience, and business strategy. The company operates with a lean organizational structure, focusing on R&D and strategic partnerships. Specific leadership details would require access to the latest corporate filings.
Top Products and Market Share
Key Offerings
- ADD-372 (mGlu2/3 PAM): A positive allosteric modulator (PAM) for metabotropic glutamate receptors 2 and 3 (mGlu2/3). It is in development for major depressive disorder (MDD) and potentially other psychiatric conditions. Competitors in the MDD space include pharmaceutical giants like Pfizer (Paxil), Eli Lilly (Prozac), and AbbVie (Trintellix), as well as numerous smaller biotechs exploring novel mechanisms. Market share data for Addex's specific drug is not applicable as it is in clinical development.
- ADD-372 (mGlu2/3 PAM) for PTSD: Addex is also investigating ADD-372 for post-traumatic stress disorder (PTSD). This indication faces competition from existing treatments and ongoing research into new therapies, though the specific allosteric modulation approach is a differentiating factor. Market share data is not applicable.
- ADD-413 (D2 PAM): A positive allosteric modulator (PAM) of the dopamine D2 receptor. It is intended for conditions like Parkinson's disease and potentially schizophrenia. Competitors in Parkinson's include drugs from AbbVie (Duodopa), UCB (Ropinirole), and numerous others focusing on dopamine replacement and symptom management. Competitors in schizophrenia include antipsychotics from Johnson & Johnson (Invega), Otsuka (Abilify), and Lundbeck (Rexulti). Market share data is not applicable.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the segment focused on neurological and psychiatric disorders, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. There is a growing demand for innovative treatments for these complex conditions, driven by an aging population and increasing awareness of mental health. The market is competitive, with both large pharmaceutical companies and smaller biotech firms vying for breakthroughs.
Positioning
Addex Therapeutics positions itself as a leader in the development of orally available small molecule allosteric modulators targeting GPCRs. Their unique technology platform allows for fine-tuning receptor activity, potentially leading to improved efficacy and safety profiles compared to traditional receptor agonists or antagonists. Their focus on unmet medical needs in neurological and psychiatric disorders is a key differentiator.
Total Addressable Market (TAM)
The TAM for neurological and psychiatric disorders is substantial and growing, with conditions like depression, Parkinson's disease, and PTSD affecting millions globally. The global market for depression treatment alone is projected to reach tens of billions of dollars. Addex Therapeutics is positioned to address a significant portion of this TAM with its pipeline, aiming to capture market share through differentiated therapeutics.
Upturn SWOT Analysis
Strengths
- Proprietary allosteric modulator technology platform.
- Experienced management team with drug development expertise.
- Focus on high-unmet-need therapeutic areas (neurology, psychiatry).
- Potential for improved efficacy and safety profiles due to allosteric modulation.
Weaknesses
- Early-stage drug development pipeline, high risk of failure.
- Reliance on external funding and potential dilution from equity raises.
- Limited commercial infrastructure and market presence compared to large pharma.
- Long development timelines and significant capital requirements.
Opportunities
- Advancements in understanding of GPCR function and allosteric modulation.
- Growing market demand for effective treatments for neurological and psychiatric disorders.
- Potential for strategic partnerships and collaborations with larger pharmaceutical companies.
- Expansion into other therapeutic areas with unmet needs.
Threats
- Clinical trial failures or disappointing results.
- Intense competition from established pharmaceutical companies and emerging biotechs.
- Regulatory hurdles and challenges in obtaining market approval.
- Patent expirations and the emergence of generic competition for existing treatments.
- Economic downturns impacting R&D funding and investment.
Competitors and Market Share
Key Competitors
- Pfizer Inc. (PFE)
- Eli Lilly and Company (LLY)
- AbbVie Inc. (ABBV)
- Johnson & Johnson (JNJ)
- Otsuka Pharmaceutical Co., Ltd. (OTSUY)
- Lundbeck A/S (LUN.CO)
Competitive Landscape
Addex Therapeutics operates in a highly competitive landscape dominated by large pharmaceutical companies with established market presence and significant resources. Its competitive advantage lies in its specialized allosteric modulator technology, which offers a potentially novel approach to drug discovery. However, it faces challenges in terms of scale, funding, and the sheer market power of its larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historically, Addex Therapeutics has focused on building its allosteric modulator technology and advancing its pipeline through preclinical and early-stage clinical development. Growth has been in terms of scientific progress and pipeline advancement rather than revenue generation.
Future Projections: Future projections are contingent on successful clinical trial outcomes and regulatory approvals. Analyst estimates, if available, would likely focus on the potential peak sales of its lead candidates and the valuation of the company upon successful milestones.
Recent Initiatives: Recent initiatives have focused on advancing its lead programs (ADD-372 and ADD-413) through clinical trials, potentially seeking strategic partnerships, and managing its cash runway.
Summary
Addex Therapeutics is a clinical-stage biopharmaceutical company with a promising allosteric modulator technology. Its focus on neurological and psychiatric disorders addresses significant unmet medical needs. While its specialized technology is a strength, the company faces high risks inherent in drug development and intense competition. Effective management of its R&D pipeline, securing funding, and navigating regulatory pathways are crucial for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations pages
- SEC Filings (e.g., 20-F)
- Financial news outlets
- Industry analysis reports
Disclaimers:
This information is for informational purposes only and should not be construed as financial advice. Stock market investments are subject to risk, and investors should conduct their own due diligence before making any investment decisions. Market share data for clinical-stage companies is an estimation based on competitive landscape and potential market penetration, not actual sales.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Addex Therapeutics Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-01-29 | Co-Founder, CEO & Director Mr. Timothy Mark Dyer | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | |
Full time employees 2 | |||
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.